Evidence map›Paper›PMID 22924552›Full record

ReviewEuropean journal of clinical investigation2012

Immune-mediated β-cell death in type 1 diabetes: lessons from human β-cell lines.

Yaíma L Lightfoot, Jing Chen, Clayton E Mathews

Open access · bronzeAbstract readReview
In one paragraph

Review in European journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Distinct differences in the responses of the human pancreatic β-cell line EndoC-βH1 and human islets to proinflammatory cytokines.American journal of physiology. Regulatory, integrative and comparative physiology · 2015
    Article
  12. In search of a surrogate: engineering human beta cell lines for therapy.Trends in endocrinology and metabolism: TEM · 2014
    Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yaíma L LightfootDepartment of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, USA.
Jing Chen
Clayton E Mathews
University of Florida · US

Funding

mt-Nd2 and Resistance to Autoimmune DiabetesR01DK074656 · NIDDK · UNIVERSITY OF FLORIDA · PI MATHEWS, CLAYTON E · 2006 to 2015
$2.8M
mt-Nd2 and resistance to autoimmune diabetesR56DK074656 · NIDDK · UNIVERSITY OF FLORIDA · PI MATHEWS, CLAYTON E · 2011 to 2011
$107k
NIDDK NIH HHS DK074656NIDDK NIH HHS R01 DK074656NIDDK NIH HHS R56 DK074656
6 · The paper itself

Abstract

Type 1 diabetes (T1D) is a chronic, multifactorial disorder that results from a contretemps of genetic and environmental factors. Autoimmune attack and functional inhibition of the insulin-producing β cells in the pancreas lead to the inability of β cells to metabolize glucose, and thus results the hallmark clinical symptom of diabetes: abnormally high blood glucose levels. Treatment and protection from T1D require a detailed knowledge of the molecular effectors and the mechanism(s) of cell death leading to β-cell demise. Primary islets and surrogate β cells have been utilized in vitro to investigate in isolation-specific mechanisms associated with progression to T1D in vivo. This review focuses on the data obtained from these experiments. Studies using transformed β cells of human sources are described.

Indexed as

AutoimmunityCell DeathCell LineDiabetes Mellitus, Type 1HumansInsulin-Secreting CellsPancreas

Identifiers

PMID22924552
PMCPMC3703770
OpenAlexW2130239935

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.